Private Equity in ABA Explained for Mere Mortals

The Emails Are Not Going to Stop

ACROSS THE UNITED STATES — if you own an ABA practice, someone from a private equity firm has probably emailed you this year. The note is friendly and vague. They admire what you’ve built, they’re “investing in the autism services space,” and they’d love 20 minutes on your calendar.

I know that email well. I founded a pediatric therapy company offering ABA, speech, and occupational therapy, and grew it from a blank legal pad to eight clinics and 250 full-time employees. Somewhere around clinic number two, the calls started, and nobody ever explained the machine behind them to me. So here it is, as simply as I can draw it. Now, before you send me a message on LinkedIn explaining what I got wrong, please realize that what follows is simplified. There are many variations on the PE theme, but this gives you the overarching structure of how it all works.

Private equity runs on five steps: raise a fund, hunt for companies, buy them with a mix of money, grow them, and sell them within four to six years. Everything else is detail.

The machine has been busy in our field. Researchers led by Brown University’s Daniel Arnold counted 574 autism service sites acquired by private equity between 2015 and 2024, across 42 states, according to a research letter published in JAMA Pediatrics in January 2026. So the odds are good that this article describes the person who emailed you last week.

Step One: They Raise a Fund

A private equity firm does not mainly invest its own money. It raises a fund, a pool of committed capital from pension funds, university endowments, insurance companies, and wealthy families. Those investors are called limited partners, or LPs; they put up the money and stay out of the driving seat. The firm itself is the general partner, or GP. It picks the investments, runs the deals, and answers to the LPs for the results.

The firm earns two kinds of pay: a management fee, typically around 2 percent a year on the money it oversees, and a share of the profits when companies are sold, often 20 percent, interestingly referred to as carried interest. A standard fund lives about ten years. Roughly the first half is for buying companies; the rest is for selling them and handing the LPs their money back, with a return.

That ten-year clock is the single most important thing to understand about your buyer. They are not buying your company to keep it forever. The exit is planned before your ink dries. Warren Buffett likes to hold forever; everyone else tends to resell companies they buy.

Step Two: They Hunt for Companies Like Yours

Every fund has a shopping list. In general, buyers want steady recurring revenue, an industry too fragmented for any one player to dominate, room to grow, industry tailwinds, and owners who built something real but never systematized it. ABA therapy checks every box: autism insurance mandates exist in all 50 states, diagnosis rates keep rising, thousands of small independent providers dot the map, and reimbursement recurs session after session, week after week, month after month.

On a spreadsheet at a PE firm in Manhattan, a well-run ABA practice looks like a subscription business with a waiting list.

When a fund evaluates a specific practice, the checklist gets sharper: the ratio of BCBAs to technicians, payer mix, clinical quality, authorization denial rates, clinician turnover, and whether the books are clean. Practices strong on those measures command the top of the price range. Practices that live in a shoebox of receipts do not.

The Four Words Decide The Value of Your ABA Company

EBITDA. Earnings before interest, taxes, depreciation, and amortization. In plain English: the operating profit your business throws off, before financing costs and accounting noise. If your practice collects $5 million in revenue and spends $4 million on wages, rent, insurance, and supplies, your EBITDA is about $1 million. Buyers then adjust it, adding back one-time costs and personal expenses run through the business (your above-market owner salary, the lawyer bill from that one bad year, the truck). The result, adjusted EBITDA, is the number every offer is built on.

Multiple. The price of a business expressed in years of EBITDA. A practice with $1 million of adjusted EBITDA that sells “at 5x” fetches $5 million. By 2025 and 2026 market benchmarks, small ABA practices generally trade at roughly 4 to 7 times EBITDA, while large multi-state platforms with strong clinical governance trade at roughly 12 to 15 times.

Multiple arbitrage. The gap between those two numbers is where the real money is made. Suppose a fund buys eight practices, each with $1 million of EBITDA, at 5x apiece. Total spent: $40 million. Combined under one brand with one billing office, the group is now a platform with $8 million of EBITDA, and platforms price at 12x: $96 million. The parts more than doubled in value without a single additional therapy hour being delivered. This is the engine behind every roll-up in ABA, and it is why the buyer can pay you a full price and still expect to profit.

Leverage. Borrowed money. Most PE purchases are leveraged buyouts, financed with debt, in which 50 to 60 percent of the purchase price typically comes from a lender rather than the fund. The catch, and it is a big one: the loan does not sit with the firm in New York. It is recorded on the acquired company’s balance sheet, and the clinics repay it from session revenue.

Step Three: They Buy With Three Kinds of Money

Put the vocabulary together and a real offer takes shape. Say your practice has $1 million of adjusted EBITDA and the buyer offers 5x: $5 million. That price arrives in layers. The fund might borrow $2.5 million, put in $2 million of its LPs’ equity, and ask you to roll over $500,000. A seller rollover means part of your sale proceeds, usually 10 to 20 percent of the price, is reinvested as a small ownership stake in the buyer’s platform instead of paid to you in cash. Some offers include an earnout: payments contingent on the practice hitting future targets. Treat earnouts skeptically: one 2026 analysis of deal outcomes found only 47 percent pay out at 90 percent or more of their maximum, and 19 percent pay nothing.

Cash at closing is the only guaranteed money. The rollover is a bet on the platform’s future. The earnout is a bet on targets you no longer fully control. Price the bets accordingly.

Step Four: They Grow the Company

For the next several years, the platform does what its name suggests: it builds. Billing, credentialing, HR, and intake move to a central office. New clinics open. More practices get bolted on as add-ons. Margins get scrutinized in ways most founders never attempted. Some of this makes companies better; centralized authorization teams and real financial reporting are things many independents genuinely lack. Sometimes PE management of a company shows up as pressure on billable hours and staffing ratios that clinicians feel immediately. That is why the firm you decide to partner with is exceedingly important (but that is for another article).

The end state is what the big names in our industry already are. BlueSprig was formed by KKR in 2017. Centria is backed by Thomas H. Lee Partners. Hopebridge belongs to Arsenal Capital Partners. Behavioral Innovations, a Texas platform of roughly 80 locations, sold in 2024 for about $300 million at approximately 15 times EBITDA. Every one of them started as somebody’s single clinic.

Step Five: They Sell (ideally) in Four to Six Years

The exit is a sale to a larger fund, a strategic acquirer, or, occasionally, the public markets. Return to our $5 million example to see why the math obsesses them. Suppose that over five years the practice’s EBITDA doubles to $2 million through add-ons and new sites, and it sells inside a platform at 10x: $20 million. Repay the loan (call it the full $2.5 million, to keep the arithmetic simple) and about $17.5 million remains for the shareholders, who put in $2.5 million. Without borrowing, the fund would have turned $5 million into $20 million, a 4x return. With borrowing, $2.5 million became roughly 7x. That is why they borrow. And your rolled-over $500,000? In this happy scenario, it multiplied too, which is the honest appeal of the rollover.

Now run the film backward, because leverage magnifies in both directions. Doreen Granpeesheh spent nearly three decades building the Center for Autism and Related Disorders (CARD) to 265 clinics, then sold it to Blackstone in 2018 in a deal that valued the company at roughly $600 million. In June 2023, CARD filed for Chapter 11 bankruptcy carrying more than $240 million in debt against about $2 million of cash.

Leverage (debt) is a magnifier. It turns good years into great ones and bad years into bankruptcy filings.

None of this means an owner should never sell, and none of it means the person emailing you is a villain. It means the two of you are playing different games on different clocks, and only one of you has played before. The more you understand how PE works, the better off you are.

AT A GLANCE

SOURCES & REFERENCES